Float Short %

21.79

Margin Of Safety %

Put/Call OI Ratio

1.11

EPS Next Q Diff

-1.59

EPS Last/This Y

3.68

EPS This/Next Y

-2.61

Price

45.19

Target Price

Analyst Recom

1.23

Performance Q

51.36

Relative Volume

1.31

Beta

0.36

Ticker: ANAB

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-09	ANAB	43.8	2.64	0.00	21486
2025-12-10	ANAB	45.01	2.64	4.00	21488
2025-12-11	ANAB	45.76	2.65	5.78	21457
2025-12-12	ANAB	44.94	2.54	0.00	20817
2025-12-15	ANAB	45.46	2.54	2.20	20818
2025-12-16	ANAB	45.1	2.53	0.00	20785
2025-12-17	ANAB	45.63	2.53	5.00	20788
2025-12-18	ANAB	47.58	2.53	1.59	20788
2025-12-19	ANAB	48.99	2.52	1.95	20744
2025-12-22	ANAB	50.26	1.24	3.80	10050
2025-12-23	ANAB	50.08	1.21	9.90	9927
2025-12-26	ANAB	50	1.18	228.00	9803
2025-12-29	ANAB	51.03	1.18	10.69	9826
2025-12-30	ANAB	48.12	1.16	0.04	9758
2025-12-31	ANAB	48.54	1.16	9.76	9770
2026-01-02	ANAB	45.02	1.12	0.03	9610
2026-01-05	ANAB	43.24	1.13	2.46	9591
2026-01-06	ANAB	43.85	1.12	5.20	9623
2026-01-07	ANAB	45.18	1.11	4.29	9562
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-09	ANAB	43.80	229.1	-26.0	-1.47
2025-12-10	ANAB	45.03	229.1	-27.8	-1.47
2025-12-11	ANAB	45.75	229.1	-27.4	-1.47
2025-12-12	ANAB	44.88	229.1	-25.9	-1.47
2025-12-15	ANAB	45.56	229.1	-27.2	-1.47
2025-12-16	ANAB	45.56	229.1	-26.8	-1.47
2025-12-17	ANAB	45.63	229.1	-27.2	-1.47
2025-12-18	ANAB	47.62	229.1	-28.4	-1.44
2025-12-19	ANAB	49.06	232.9	-28.0	-1.44
2025-12-22	ANAB	50.76	232.9	-28.0	-1.44
2025-12-23	ANAB	50.17	232.9	-26.6	-1.44
2025-12-26	ANAB	50.03	232.9	-26.7	-1.44
2025-12-29	ANAB	50.94	232.9	-27.4	-1.44
2025-12-30	ANAB	48.24	232.9	-24.6	-1.44
2025-12-31	ANAB	48.49	232.9	-26.9	-1.44
2026-01-02	ANAB	44.95	232.9	-23.7	-1.44
2026-01-05	ANAB	43.23	232.9	-25.1	-1.44
2026-01-06	ANAB	43.91	232.9	-27.4	-1.44
2026-01-07	ANAB	45.19	232.9	-27.9	-1.44
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-09	ANAB	-2.68	-18.52	22.77
2025-12-10	ANAB	-2.68	-18.52	22.52
2025-12-11	ANAB	-2.68	-18.52	22.52
2025-12-12	ANAB	-2.68	-18.52	22.52
2025-12-15	ANAB	-2.68	-18.52	22.66
2025-12-16	ANAB	-2.45	-18.52	22.66
2025-12-17	ANAB	-2.45	-18.52	22.66
2025-12-18	ANAB	-4.42	-18.52	22.66
2025-12-19	ANAB	-4.42	-18.52	22.66
2025-12-22	ANAB	-4.12	-18.52	22.66
2025-12-23	ANAB	-4.12	-18.52	22.66
2025-12-26	ANAB	-5.40	-18.52	21.81
2025-12-29	ANAB	-5.40	-18.50	21.79
2025-12-30	ANAB	-5.44	-18.50	21.79
2025-12-31	ANAB	-5.44	-18.50	21.79
2026-01-02	ANAB	-5.44	-18.50	21.79
2026-01-05	ANAB	-4.38	-18.57	21.79
2026-01-06	ANAB	-4.38	-18.57	21.79
2026-01-07	ANAB	-5.68	-18.57	21.79
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.52

Avg. EPS Est. Current Quarter

0.96

Avg. EPS Est. Next Quarter

-1.07

Insider Transactions

-5.68

Institutional Transactions

-18.57

Beta

0.36

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

13.9

Max Drawdown 5-Year %

-69.3

Target Price

P/E

Forward P/E

PEG

P/S

7.39

P/B

P/Free Cash Flow

EPS

-2.82

Average EPS Est. Cur. Y

-1.44

EPS Next Y. (Est.)

-4.05

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-49.94

Relative Volume

1.31

Return on Equity vs Sector %

260.6

Return on Equity vs Industry %

275.8

EPS 1 7Days Diff

EPS 1 30Days Diff

0.35

EBIT Estimation

-27.9

AnaptysBio, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 136

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

stock quote shares ANAB – AnaptysBio Inc Stock Price stock today

news today ANAB – AnaptysBio Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch ANAB – AnaptysBio Inc yahoo finance google finance

stock history ANAB – AnaptysBio Inc invest stock market

stock prices ANAB premarket after hours

ticker ANAB fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ANAB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y